Modality
Gene Editing
MOA
STINGag
Target
HER2
Pathway
NF-κB
MDS
Development Pipeline
Preclinical
Oct 2018
→ Mar 2029
PreclinicalCurrent
NCT04693378
1,625 pts·MDS
2018-10→2029-03·Terminated
1,625 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-03-062.9y awayInterim· MDS
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Preclinical
Termina…
Catalysts
Interim
2029-03-06 · 2.9y away
MDS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04693378 | Preclinical | MDS | Terminated | 1625 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT |